Humana Inc. (NYSE:HUM) Shares Purchased by Atwood & Palmer Inc.

Atwood & Palmer Inc. grew its position in shares of Humana Inc. (NYSE:HUM) by 64.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 153 shares of the insurance provider’s stock after purchasing an additional 60 shares during the quarter. Atwood & Palmer Inc.’s holdings in Humana were worth $39,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in HUM. FNY Investment Advisers LLC grew its stake in Humana by 6,647.5% during the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after buying an additional 26,856 shares during the last quarter. PDT Partners LLC increased its holdings in shares of Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after acquiring an additional 2,660 shares during the period. Ontario Teachers Pension Plan Board raised its position in Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after purchasing an additional 71,910 shares during the last quarter. Swedbank AB boosted its stake in Humana by 3.0% during the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock worth $33,567,000 after purchasing an additional 3,085 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in Humana during the 3rd quarter worth $948,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $282.63 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $273.81 and a two-hundred day moving average of $307.18. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $415.73. The stock has a market cap of $34.03 billion, a P/E ratio of 25.03, a PEG ratio of 2.13 and a beta of 0.55.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, research analysts predict that Humana Inc. will post 16.11 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.25%. Humana’s dividend payout ratio (DPR) is 31.36%.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HUM has been the subject of a number of research reports. Wells Fargo & Company reduced their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. UBS Group reduced their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. Barclays lifted their target price on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Morgan Stanley upped their price target on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Finally, Royal Bank of Canada lowered their price objective on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $302.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.